logo

For the Inventor, By the Inventor

London, United Kingdom

Richard Fagan

This inventor holds 9 USPTO granted patents and 1 published patent application. Top assignee: Ares Trading S.a.. Active years: 2008-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Fagan. Retrieved from https://idiyas.com/inventor/richard-fagan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 

Average Co-Inventor Count = 5.3

ph-index = 1

Forward Citations = 53(Granted Patents)


Company Filing History:

goldMedal9 out of 139 
 
Ares Trading S.a.
 patents

Years Active: 2008-2012

Loading Chart...
9 patents (USPTO):Explore Patents
1. 8124748 - Cell surface glycoprotein (2012-02-28),
2. 7803383 - Method of treatment comprising administration of a cytokine antagonist molecule (2010-09-28),
3. 7700724 - Isolated INSP 163 protein (2010-04-20),
4. 7622555 - Cytokine antagonist molecules (2009-11-24),
5. 7619065 - Cystine-knot fold protein (2009-11-17),
6. 7557079 - Metalloprotease proteins (2009-07-07),
7. 7531508 - Splice variant of the human pituitary growth hormone (2009-05-12),
8. 7514533 - TNF-like secreted protein (2009-04-07),
9. 7341851 - IL-8 like protein (2008-03-11),

Title: Richard Fagan: Innovator in Glycoprotein Research

Introduction

Richard Fagan is a notable inventor based in London, GB. He has made significant contributions to the field of biotechnology, particularly in the area of glycoproteins. With a total of nine patents to his name, Fagan's work has the potential to impact the diagnosis, prevention, and treatment of various diseases.

Latest Patents

Among his latest patents is a novel protein identified as INSP201, which is classified as a cell surface glycoprotein. This invention focuses on the use of INSP201 and its associated nucleic acid sequences for diagnosing, preventing, and treating diseases. Another significant patent involves a method of treatment that utilizes a cytokine antagonist molecule, specifically a protein sequence known as INSP052EC. This invention aims to address diseases related to the excessive expression and/or secretion of cytokines.

Career Highlights

Richard Fagan is currently associated with Ares Trading S.a., where he continues to advance his research and innovations. His work has garnered attention in the scientific community, contributing to the understanding of glycoproteins and their applications in medicine.

Collaborations

Fagan has collaborated with notable colleagues, including Christine Power and Christopher Benjamin Phelps. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of their collective research.

Conclusion

Richard Fagan's contributions to the field of biotechnology through his innovative patents highlight his role as a leading inventor. His work on glycoproteins and cytokine antagonists showcases the potential for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…